Ginkgo Bioworks Holdings, Inc. (DNA) Announced Q4 2025 Earnings on February 26, 2026, Reporting "Cell engineering revenue was $26 million in the fourth quarter of 2025"

Ginkgo Bioworks Holdings, Inc. reported its fourth quarter 2025 financial results.

Cell engineering revenue was $26 million in the fourth quarter of 2025, down 26 percent compared to the fourth quarter of 2024.

For the full year, cell engineering revenue was $133 million in 2025.

The biosecurity business generated $7 million of revenue in the fourth quarter and $37 million of revenue in the full year 2025.

Total adjusted EBITDA in the fourth quarter of 2025 was negative $36 million, and cash burn in the fourth quarter of 2025 was $47 million.

Management stated that the technological and business focus for 2026 will be on investing in the category of autonomous labs. To facilitate this focus, the company announced it will be divesting its biosecurity business into a separate private entity where Ginkgo will hold a minority position.

The company plans to systematically decommission traditional lab benches and move more work onto a single large autonomous lab, aiming to grow from 50 racks to 100 racks by the first half of the year.

For forward guidance, management noted they will not be providing revenue guidance for 2026, but expect overall cash burn guidance to be in the range of $125 million to $150 million.

The company also announced a new $47 million contract with the Department of Energy to build a 97 robot autonomous lab at Pacific Northwest National Labs.

Additionally, management highlighted a project with OpenAI using GPT 5 as an AI scientist to design experiments submitted to the autonomous lab.